[A19-48] Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Last updated 02.09.2019
Project no.:
A19-48
Commission:
Commission awarded on 29.05.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with ALK-positive advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy, or after crizotinib and at least one other ALK TKI
Added benefit versus appropriate comparator therapy not proven due to a lack of suitable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A22-31 | Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-11-22 A G-BA decision was published.